A model to assess the cost–effectiveness of pharmacogenomics tests in chronic heart failure: the case of ivabradine. (October 2016)

• Record Type: Journal Article
• Authors: Iliza, Ange C; Matteau, Alexis; Guertin, Jason R; Mitchell, Dominic; Fanton-Aita, Fiorella; Dubois, Anick; Dubé, Marie-Pierre; Tardif, Jean-Claude; LeLorier, Jacques
• Is Part Of: Pharmacogenomics. Volume 17:Number 15(2016)
• Page Start: 1693
• Page End: 1706
• Publication Date: 2016-10
• Subjects: cardiovascular diseases -- chronic heart failure -- cost%ndash;effectiveness -- Markov model -- New York Heart Association -- pharmacogenomics tests -- quality-adjusted life years; Pharmacogenomics -- Periodicals; 615.1
• DOI: 10.2217/pgs-2016-0054
• Languages: English
• ISSNs: 1462-2416

Abstract

Pharmacogenomics (PGx) tests have the potential of improving the effectiveness of expensive new drugs by predicting the likelihood, for a particular patient, to respond to a treatment. The objective of this study was to develop a pharmacoeconomic model to determine the characteristics and the cost–effectiveness of a hypothetical PGx test, which would identify patients who are most likely to respond to an expensive treatment for chronic heart failure. For this purpose, we chose the example of ivabradine. Our results suggest that the use of a PGx test that could select a subgroup of patients to be treated with an expensive drug has the potential to provide more efficient drug utilization.